Alzheimer’s Disease Study Patient Referral Strategy

This document is a study report detailing Walgreens' approach to increasing participation in clinical trials for Alzheimer's disease. It outlines a phase 1 randomized, double-blind, placebo-controlled study aimed at evaluating a next-generation monoclonal antibody for Alzheimer's treatment. The report describes how Walgreens utilized real-world data to identify eligible patient populations within a specific geographic area, emphasizing their commitment to engaging underrepresented communities. The methodology includes creating culturally sensitive outreach materials and employing a patient cohort browser tool to streamline participant identification and communication. The results indicate that Walgreens achieved a higher referral rate of Hispanic/Latino participants compared to national averages, highlighting their effective community-centered approach. The report concludes by affirming Walgreens' role in making clinical trials more accessible and equitable, thereby enhancing patient representation in research efforts.